AAPL344.82-2.29 (-0.66%) ▼|ABBV285.63-0.76 (-0.27%) ▼|ABT103.47+0.37 (+0.36%) ▲|ACN246.40+11.24 (+4.78%) ▲|ADBE248.32-0.04 (-0.02%) ▼|AMAT407.12+11.19 (+2.83%) ▲|AMD561.27+1.01 (+0.18%) ▲|AMGN452.29+4.34 (+0.97%) ▲|AMT179.01-4.83 (-2.62%) ▼|AMZN253.58+0.48 (+0.19%) ▲|AVGO345.00+2.67 (+0.78%) ▲|AXP316.40+3.49 (+1.11%) ▲|BA165.92-2.26 (-1.34%) ▼|BAC50.84+0.16 (+0.31%) ▲|BKNG148.55-1.59 (-1.06%) ▼|BLK1,146.88+10.83 (+0.95%) ▲|BMY61.01-0.55 (-0.89%) ▼|BNY148.20+0.62 (+0.42%) ▲|BRK-B543.01+0.02 (+0.00%) ▲|C123.50+0.81 (+0.66%) ▲|CAT709.64-3.67 (-0.51%) ▼|CL91.98-0.19 (-0.21%) ▼|CMCSA21.66-0.19 (-0.85%) ▼|COF204.31+0.87 (+0.43%) ▲|COP148.95+0.99 (+0.67%) ▲|COST982.90-9.23 (-0.93%) ▼|CRM243.26+2.37 (+0.98%) ▲|CSCO110.51-0.88 (-0.79%) ▼|CVS90.74-0.39 (-0.43%) ▼|CVX229.48+1.25 (+0.55%) ▲|DE642.59+3.01 (+0.47%) ▲|DHR237.13+5.13 (+2.21%) ▲|DIS109.20-1.03 (-0.93%) ▼|DUK124.62-0.19 (-0.15%) ▼|EMR167.91+1.64 (+0.99%) ▲|FDX302.00-5.10 (-1.66%) ▼|GD353.63-1.27 (-0.36%) ▼|GE297.86+0.20 (+0.07%) ▲|GEV864.11-30.97 (-3.46%) ▼|GILD160.07+0.99 (+0.62%) ▲|GM80.03-0.51 (-0.63%) ▼|GOOG320.98+4.15 (+1.31%) ▲|GOOGL324.62+4.04 (+1.26%) ▲|GS919.41+7.64 (+0.84%) ▲|HD320.83+2.33 (+0.73%) ▲|HON218.80-0.01 (0.00%) ▼|IBM252.04+1.79 (+0.72%) ▲|INTC93.26-0.48 (-0.51%) ▼|INTU333.00+4.55 (+1.39%) ▲|ISRG447.90+2.02 (+0.45%) ▲|JNJ269.83+1.10 (+0.41%) ▲|JPM337.26+1.47 (+0.44%) ▲|KO91.66+0.48 (+0.53%) ▲|LIN507.09-1.56 (-0.31%) ▼|LLY1,292.56+10.65 (+0.83%) ▲|LMT620.84-2.15 (-0.35%) ▼|LOW199.79+1.61 (+0.81%) ▲|LRCX247.76+6.91 (+2.87%) ▲|MA614.07+4.22 (+0.69%) ▲|MCD251.93+2.46 (+0.99%) ▲|MDLZ62.12-0.24 (-0.38%) ▼|MDT95.56+1.61 (+1.71%) ▲|META616.33-3.87 (-0.62%) ▼|MMM172.33+0.75 (+0.44%) ▲|MO73.31-0.18 (-0.24%) ▼|MRK141.58-0.25 (-0.17%) ▼|MS187.89+0.98 (+0.52%) ▲|MSFT529.84-1.49 (-0.28%) ▼|MU968.67+39.91 (+4.30%) ▲|NEE81.77-0.65 (-0.79%) ▼|NFLX61.87-0.65 (-1.04%) ▼|NKE37.53-0.04 (-0.09%) ▼|NOW153.52-1.26 (-0.81%) ▼|NVDA217.52-0.43 (-0.20%) ▼|ORCL130.78+0.25 (+0.19%) ▲|PEP132.45-1.05 (-0.79%) ▼|PFE29.73-0.08 (-0.25%) ▼|PG159.07-0.16 (-0.10%) ▼|PLTR195.32-3.42 (-1.72%) ▼|PM202.57-0.05 (-0.02%) ▼|QCOM183.07-1.10 (-0.60%) ▼|RTX195.30+0.70 (+0.36%) ▲|SBUX103.24+0.20 (+0.19%) ▲|SCHW88.58-0.72 (-0.81%) ▼|SO92.58-0.08 (-0.08%) ▼|SPG211.83-0.46 (-0.21%) ▼|T20.78-0.16 (-0.76%) ▼|TMO710.53+17.51 (+2.53%) ▲|TMUS145.19-1.64 (-1.12%) ▼|TSLA399.09-8.37 (-2.05%) ▼|TXN308.84-0.08 (-0.02%) ▼|UBER64.94-0.84 (-1.28%) ▼|UNH414.28+3.89 (+0.95%) ▲|UNP299.13-0.75 (-0.25%) ▼|UPS104.92-1.17 (-1.10%) ▼|USB59.61-0.13 (-0.22%) ▼|V401.52-0.34 (-0.08%) ▼|VZ43.52-0.42 (-0.94%) ▼|WFC83.44+0.78 (+0.94%) ▲|WMT118.83-0.49 (-0.41%) ▼|XOM181.67+1.76 (+0.98%) ▲|AAPL344.82-2.29 (-0.66%) ▼|ABBV285.63-0.76 (-0.27%) ▼|ABT103.47+0.37 (+0.36%) ▲|ACN246.40+11.24 (+4.78%) ▲|ADBE248.32-0.04 (-0.02%) ▼|AMAT407.12+11.19 (+2.83%) ▲|AMD561.27+1.01 (+0.18%) ▲|AMGN452.29+4.34 (+0.97%) ▲|AMT179.01-4.83 (-2.62%) ▼|AMZN253.58+0.48 (+0.19%) ▲|AVGO345.00+2.67 (+0.78%) ▲|AXP316.40+3.49 (+1.11%) ▲|BA165.92-2.26 (-1.34%) ▼|BAC50.84+0.16 (+0.31%) ▲|BKNG148.55-1.59 (-1.06%) ▼|BLK1,146.88+10.83 (+0.95%) ▲|BMY61.01-0.55 (-0.89%) ▼|BNY148.20+0.62 (+0.42%) ▲|BRK-B543.01+0.02 (+0.00%) ▲|C123.50+0.81 (+0.66%) ▲|CAT709.64-3.67 (-0.51%) ▼|CL91.98-0.19 (-0.21%) ▼|CMCSA21.66-0.19 (-0.85%) ▼|COF204.31+0.87 (+0.43%) ▲|COP148.95+0.99 (+0.67%) ▲|COST982.90-9.23 (-0.93%) ▼|CRM243.26+2.37 (+0.98%) ▲|CSCO110.51-0.88 (-0.79%) ▼|CVS90.74-0.39 (-0.43%) ▼|CVX229.48+1.25 (+0.55%) ▲|DE642.59+3.01 (+0.47%) ▲|DHR237.13+5.13 (+2.21%) ▲|DIS109.20-1.03 (-0.93%) ▼|DUK124.62-0.19 (-0.15%) ▼|EMR167.91+1.64 (+0.99%) ▲|FDX302.00-5.10 (-1.66%) ▼|GD353.63-1.27 (-0.36%) ▼|GE297.86+0.20 (+0.07%) ▲|GEV864.11-30.97 (-3.46%) ▼|GILD160.07+0.99 (+0.62%) ▲|GM80.03-0.51 (-0.63%) ▼|GOOG320.98+4.15 (+1.31%) ▲|GOOGL324.62+4.04 (+1.26%) ▲|GS919.41+7.64 (+0.84%) ▲|HD320.83+2.33 (+0.73%) ▲|HON218.80-0.01 (0.00%) ▼|IBM252.04+1.79 (+0.72%) ▲|INTC93.26-0.48 (-0.51%) ▼|INTU333.00+4.55 (+1.39%) ▲|ISRG447.90+2.02 (+0.45%) ▲|JNJ269.83+1.10 (+0.41%) ▲|JPM337.26+1.47 (+0.44%) ▲|KO91.66+0.48 (+0.53%) ▲|LIN507.09-1.56 (-0.31%) ▼|LLY1,292.56+10.65 (+0.83%) ▲|LMT620.84-2.15 (-0.35%) ▼|LOW199.79+1.61 (+0.81%) ▲|LRCX247.76+6.91 (+2.87%) ▲|MA614.07+4.22 (+0.69%) ▲|MCD251.93+2.46 (+0.99%) ▲|MDLZ62.12-0.24 (-0.38%) ▼|MDT95.56+1.61 (+1.71%) ▲|META616.33-3.87 (-0.62%) ▼|MMM172.33+0.75 (+0.44%) ▲|MO73.31-0.18 (-0.24%) ▼|MRK141.58-0.25 (-0.17%) ▼|MS187.89+0.98 (+0.52%) ▲|MSFT529.84-1.49 (-0.28%) ▼|MU968.67+39.91 (+4.30%) ▲|NEE81.77-0.65 (-0.79%) ▼|NFLX61.87-0.65 (-1.04%) ▼|NKE37.53-0.04 (-0.09%) ▼|NOW153.52-1.26 (-0.81%) ▼|NVDA217.52-0.43 (-0.20%) ▼|ORCL130.78+0.25 (+0.19%) ▲|PEP132.45-1.05 (-0.79%) ▼|PFE29.73-0.08 (-0.25%) ▼|PG159.07-0.16 (-0.10%) ▼|PLTR195.32-3.42 (-1.72%) ▼|PM202.57-0.05 (-0.02%) ▼|QCOM183.07-1.10 (-0.60%) ▼|RTX195.30+0.70 (+0.36%) ▲|SBUX103.24+0.20 (+0.19%) ▲|SCHW88.58-0.72 (-0.81%) ▼|SO92.58-0.08 (-0.08%) ▼|SPG211.83-0.46 (-0.21%) ▼|T20.78-0.16 (-0.76%) ▼|TMO710.53+17.51 (+2.53%) ▲|TMUS145.19-1.64 (-1.12%) ▼|TSLA399.09-8.37 (-2.05%) ▼|TXN308.84-0.08 (-0.02%) ▼|UBER64.94-0.84 (-1.28%) ▼|UNH414.28+3.89 (+0.95%) ▲|UNP299.13-0.75 (-0.25%) ▼|UPS104.92-1.17 (-1.10%) ▼|USB59.61-0.13 (-0.22%) ▼|V401.52-0.34 (-0.08%) ▼|VZ43.52-0.42 (-0.94%) ▼|WFC83.44+0.78 (+0.94%) ▲|WMT118.83-0.49 (-0.41%) ▼|XOM181.67+1.76 (+0.98%) ▲|
10 C
New York
Wednesday, October 28, 2026

Tag: testing

newsFORsourcecompanycontentinformation1releasesmarket

PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy

               

Autonomous Vehicle Simulation Solutions Research Report 2025-2034: Market to Grow at a CAGR of 20.4% to Reach $7.3 Billion – Boost Developments with Cloud-Based,...

The Autonomous Vehicle Simulation Solutions Market, valued at USD 1.4 billion in 2025, is set to grow at a 20.4% CAGR, reaching USD 7.3 billion by 2034. This market is crucial for testing self-driving systems, using AI and cloud-based simulations to improve safety and development efficiency. 
The Autonomous Vehicle Simulation Solutions Market, valued at USD 1.4 billion in 2025, is set to grow at a 20.4% CAGR, reaching USD 7.3 billion by 2034. This market is crucial for testing self-driving systems, using AI and cloud-based simulations to improve safety and development efficiency.

Diagnostic Electrocardiograph/ECG Market worth US$15.18 billion by 2032 with 7.4% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., June 13, 2025 /PRNewswire/ -- The global Diagnostic Electrocardiograph/ECG Market, valued at US$8.59 billion in 2024 stood at US$9.19 billion in 2025 and...

Steer-by-Wire Market Grows as Automakers Embrace Digital Steering for EVs and Smart Mobility | Valuates Reports

BANGALORE, India, June 13, 2025 /PRNewswire/ -- Steer By Wire Market is Segmented by Type (EPS, SBW), by Application (Commercial Vehicle, Passenger Car): Global Opportunity Analysis...

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

CLEVELAND, June 13, 2025 /PRNewswire/ -- Primary Investigator, Bernardo Cortese MD, proudly announces the successful completion of patient enrollment in the TRANSFORM II randomized...

Bitget Wallet Launches Pharos and CESS Testnet Campaigns, Distributing 200,000 Tokens

Bitget Wallet, the leading non-custodial crypto wallet, has launched two new testnet campaigns in collaboration with blockchain infrastructure projects ...

Weekly Recap: 11 Health Press Releases You Need to See

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including advances in sleep apnea treatments, fall detection for seniors...

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival.

Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses

-- Breadth of presentations, including one oral and two flash talks, showcase Blueprint Medicines' leadership role in advancing care for patients with systemic mastocytosis...

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin’s Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities

Gatorade® and F1 ACADEMY™ Launch Groundbreaking Partnership to Fuel the Future of Women’s Racing

The 5.5-year collaboration will bring elite sports science, hydration expertise, and global visibility to the next generation of female F1 drivers. Gatorade® becomes the first-ever...

Logent Group acquires HUB logistics Finland Oy and announces the intention to issue subsequent notes

Logent Finland Bidco Oy, an indirect subsidiary of SSCP Lager BidCo AB (publ) (“Logent” or the “Company”) has entered into an agreement with the shareholders of the Finnish entity HUB logistics Finland Oy (“HUB logistics” or the “Target”) to acquire all the shares in the Target (the “Acquisition”). The closing of the Acquisition is expected to take effect on 23 June 2025 and is subject to customary conditions precedents.

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

– Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients –

LabConnect Selects Deloitte to Streamline Financial and Business Operations

JOHNSON CITY, Tenn., June 12, 2025 /PRNewswire/ -- LabConnect, a leading provider of global central laboratory and support services for clinical trials, has selected...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTesting

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers